Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How often did you experience muscle cramps while on lipitor treatment?Are there any specific types of immunotherapy that work best with lurbinectedin?For what reason was advil invented?What are the side effects of lower lipitor doses?Is lipitor more effective than fish oil supplements for cholesterol?
See the DrugPatentWatch profile for kisqali
Kisqali for Metastatic Breast Cancer: What You Need to Know Kisqali, also known as ribociclib, is a targeted therapy used in the treatment of certain types of breast cancer. What is Kisqali Used for? Kisqali is FDA-approved for the treatment of metastatic breast cancer in postmenopausal women and men. It is intended for use in combination with an aromatase inhibitor to treat hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic). How Does Kisqali Work? Kisqali is a CDK 4/6 inhibitor, which means it works by blocking the activity of two enzymes called CDK 4 and CDK 6. These enzymes play a role in cell division and growth, and by blocking them, Kisqali can slow the growth of cancer cells. Clinical Data and Trial Results According to the Kisqali prescribing information, the phase III MONARCH 3 clinical trial showed that patients treated with Kisqali and an aromatase inhibitor experienced a statistically significant improvement in progression-free survival compared to those treated with an aromatase inhibitor alone. Patent and Exclusivity According to DrugPatentWatch.com [1], the U.S. patent for Kisqali expires in 2029, although a patent extension may be granted. The patent's expiration will likely allow generic versions of the drug to enter the market, potentially increasing accessibility and affordability. Side Effects and Safety Common side effects of Kisqali include fatigue, nausea, diarrhea, alopecia (hair loss), and neutropenia (low white blood cell count). Patients should discuss potential side effects with their doctor and follow recommended dosing instructions. Can Biosimilars Enter Before Patent Expiry? While biosimilars can potentially enter the market before patent expiration, it's uncertain whether they will be approved for use in metastatic breast cancer treatment prior to the patent's expiration. Biosimilars must undergo rigorous testing and approval by regulatory agencies before they can enter the market. References: [1] DrugPatentWatch.com. Kisqali (ribociclib) Patent Information. https://www.drugpatentwatch.com/patent/kisqali-ribociclib (accessed April 2023)
Other Questions About Kisqali :